Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 2,168 | 211,120 | 1,745 | 4,091 | 1,641 |
| Cost of Goods | 598 | 598 | 598 | 598 | 599 |
| Gross Profit | 1,570 | 210,522 | 1,147 | 3,493 | 1,042 |
| Operating Expenses | 177,707 | 210,777 | 179,161 | 161,783 | 147,740 |
| Operating Income | -175,539 | 343 | -177,416 | -157,692 | -146,099 |
| Interest Expense | 22,937 | 23,471 | 20,268 | 20,306 | 20,594 |
| Other Income | 122,932 | -13,032 | 27,356 | -1,490 | 5,990 |
| Pre-tax Income | -75,544 | -36,160 | -170,328 | -179,488 | -160,703 |
| Net Income Continuous | -75,544 | -36,160 | -170,328 | -179,488 | -160,703 |
| Minority Interests | -2,088 | -944 | -2,180 | -2,489 | -2,804 |
| Net Income | $-73,456 | $-35,216 | $-168,148 | $-176,999 | $-157,899 |
| EPS Basic Total Ops | -0.39 | -0.20 | -0.97 | -1.08 | -0.98 |
| EPS Basic Continuous Ops | -0.40 | -0.20 | -0.98 | -1.10 | -1.00 |
| EPS Diluted Total Ops | -0.39 | -0.20 | -0.97 | -1.08 | -0.98 |
| EPS Diluted Continuous Ops | -0.40 | -0.20 | -0.98 | -1.10 | -1.00 |
| EPS Diluted Before Non-Recurring Items | -1.02 | -0.05 | -0.96 | -1.08 | -0.98 |
| EBITDA(a) | $-173,965 | $1,939 | $-175,831 | $-156,053 | $-144,462 |